Ever-expanding landscape: Alzheimer’s – new targets and new patents

References

• 1. Matej R, Tesar A, Rusina R. Alzheimer's disease and other neurodegenerative dementias in comorbidity: a clinical and neuropathological overview. Clin. Biochem. 73, 26–31 (2019).
  Medline CASGoogle Scholar
• 2. Mufson E, Ikonomovic M, Counts S et al. Molecular and cellular pathophysiology of preclinical Alzheimer's disease. Behav. Brain Res. 311, 54–69 (2016).
  Medline CASGoogle Scholar
• 3. Kumar N, Kumar V, Anand P, Kumar V, Dwivedi A, Kumar V. Advancements in the development of multi-target directed ligands for the treatment of Alzheimer's disease. Bioorg. Med. Chem. 61, 116742 (2022).
  Medline CASGoogle Scholar
• 4. Fish P, Steadman D, Bayle E, Whiting P. New approaches for the treatment of Alzheimer's disease. Bioorg. Med. Chem. Lett. 29, 125–133 (2019).
  Medline CASGoogle Scholar
• 5. Arbo B, Riberiro M, Garcia-Segura L. Development of new treatment for Alzheimer's diseases based on the modulation of translocator protein (TSPO). Ageing Res. Rev. 54, 100943 (2019).
  Medline CASGoogle Scholar
• 6. Vaz M, Silvestre S. Alzheimer's disease: recent treatment strategies. Eur. J. Pharmacol. 887, 173554 (2020).
  Medline CASGoogle Scholar
• 7. Pradeepkiran J, Reddy P. Phosphorylated tau targeted small-molecule PROTACs for the treatment of Alzheimer's disease and tauopathies. Biochim. Biophys. Acta – Mol. Basis Dis. 1867, 166162 (2021).
  MedlineGoogle Scholar
• 8. Verma A, Waiker D, Bhardwaji B, Saraf P, Shrivastava S. The molecular mechanism, targets, and novel molecules in the treatment of Alzheimer's disease. Bioorg. Chem. 119, 105562 (2022).
  Medline CASGoogle Scholar
• 9. Lim S. The recent pharmaceutical patent landscape for Alzheimer's disease: an interview with Sang Min Lim. Pharm. Pat. Anal. 8(6), 215–216 (2019).
  CASGoogle Scholar
• 10. Lee H, Lim D, Lee J, Lim S, Pae A. Development of tau-directed small molecule modulators for Alzheimer's disease: a recent patent review (2014–2018). Pharm. Pat. Anal. 8(1), 15–39 (2019).
  CASGoogle Scholar
• 11. BASF SE. WO2021/1234191 (2021).
  Google Scholar
• 12. OHIO STATE INNOVATION FOUNDATION AND THE BRIGHAM AND WOMAN'S HOSPITAL INC. WO2019/2366251 (2019).
  Google Scholar
• 13. ABAERATA LIMITED PARTNERSHIP. WO2020/1133381 (2020).
  Google Scholar
• 14. MEDIMMUNE LIMITED AND ELI LILLY AND COMPANY. WO2021/2601931 (2021).
  Google Scholar
• 15. VLAAMS INSTITUUT VOOR BIOTECHNOLOGIE AND KATHOLIEKE UNIVERSITEIT LEUVEN. WO2019/0161231 (2019).
  Google Scholar
• 16. CENTREA DE INVESTIGACION Y DE ESTUDIOS AVANZADOS DEL INSTITUTO POLITECNICO NACIONAL AND BUSTAR ALIMENTOS S.A.P.I.DE C.V. WO2022/0765071 (2022).
  Google Scholar
• 17. CEDARS-SINAI MEDICAL CENTER AND FORTEM NEUROSCIENCES. WO2022/0316062 (2022).
  Google Scholar
• 18. AC IMMUNE SA. WO2022/0789711 (2022).
  Google Scholar
• 19. Siddiqui H, Choudhary M, Wahab A, Rahman A, Rizvi F, Wajid S. WO2021/03631081 (2021).
  Google Scholar
• 20. Swalley S. Expanding therapeutic opportunities for neurodegenerative diseases: a perspective on the important role of phenotypic screening. Bioorg. Med. Chem. 28, 115239 (2020).
  Medline CASGoogle Scholar